# ガイドライン収集・解析状況

> 自動生成: 2026-06-15 23:51 (`scripts/build_status_md.py` より)  
> データソース: `data/guidelines.json`

---

## サマリー

| 指標 | 件数 | 割合 |
|---|---:|---:|
| 総ガイドライン数 | **95** | — |
| PDF 取得完了 | 82 | 86% |
| OCR 完了 | 80 | 84% |
| 精読完了 | 79 | 83% |
| 比較完了 | 7 | 7% |
| 臨床分析完了 | 82 | 86% |
| 学習コンテンツ完了 | 82 | 86% |
| 差分抽出完了 | 0 | 0% |
| エラーあり | 0 | 0% |

**アイコン凡例:** ✅ 完了 ｜ ❌ 失敗 ｜ ⏳ 実行中 ｜ ⏭ スキップ ｜ — 未実施

---

## テーマ別サマリー

| テーマ | 総数 | FOUND | APPROVED | 精読済 | 臨床分析済 | 学習化済 | 要アクション |
|---|---:|---:|---:|---:|---:|---:|---:|
| 甲状腺疾患 | 17 | 3 | 0 | 14 | 14 | 14 | ⚠️ 3件 |
| 糖尿病 | 38 | 4 | 2 | 31 | 32 | 32 | ⚠️ 6件 |
| 脂質異常症・CVD予防 | 28 | 2 | 1 | 25 | 25 | 25 | ⚠️ 3件 |
| 心不全 | 9 | 0 | 0 | 9 | 9 | 9 | — 0件 |
| 腎臓・CKD/AKI | 17 | 0 | 0 | 16 | 17 | 17 | — 0件 |
| 高血圧 | 17 | 2 | 0 | 13 | 15 | 15 | ⚠️ 2件 |
| 内分泌・代謝（副腎・下垂体・骨代謝） | 34 | 6 | 0 | 26 | 28 | 28 | ⚠️ 6件 |

### 甲状腺疾患 — 要アクション候補

- `2016-aace-thyroid-nodule` (⚪ FOUND) — AACE/ACE/AME Medical Guidelines for the Diagnosis and Management of Thyroid Nodules — 2016 Update
  - 推奨: `workflow/state.md` で `APPROVED` または `SKIPPED` に更新
- `2019-j-jta-graves` (⚪ FOUND) — バセドウ病薬物療法のガイドライン2019
  - 推奨: `workflow/state.md` で `APPROVED` または `SKIPPED` に更新
- `2022-j-jta-hashimotos` (⚪ FOUND) — 橋本病（慢性甲状腺炎）診療の手引き 改訂版（2022）
  - 推奨: `workflow/state.md` で `APPROVED` または `SKIPPED` に更新

### 糖尿病 — 要アクション候補

- `2025-ada-standards-care` (🟡 APPROVED) — Standards of Care in Diabetes—2025
  - 推奨: `/gdrive-sync` → `/ai-ocr 2025-ada-standards-care` → `/read-guidelines 2025-ada-standards-care`
- `2023-ese-easo-obesity` (⚪ FOUND) — European Clinical Practice Guidelines for the Management of Obesity in Adults
  - 推奨: `workflow/state.md` で `APPROVED` または `SKIPPED` に更新
- `2022-j-jasso-obesity` (⚪ FOUND) — 肥満症診療ガイドライン 2022
  - 推奨: `workflow/state.md` で `APPROVED` または `SKIPPED` に更新
- `2024-j-jds-diabetes-treatment-guide` (🟡 APPROVED) — 糖尿病治療ガイド2024-2025
  - 推奨: `/gdrive-sync` → `/ai-ocr 2024-j-jds-diabetes-treatment-guide` → `/read-guidelines 2024-j-jds-diabetes-treatment-guide`
- `2020-j-jes-cushings` (⚪ FOUND) — クッシング症候群診療ガイドライン2020
  - 推奨: `workflow/state.md` で `APPROVED` または `SKIPPED` に更新
- `2023-j-joa-osteoporosis` (⚪ FOUND) — 骨粗鬆症の予防と治療ガイドライン 2023年版
  - 推奨: `workflow/state.md` で `APPROVED` または `SKIPPED` に更新

### 脂質異常症・CVD予防 — 要アクション候補

- `2025-ada-standards-care` (🟡 APPROVED) — Standards of Care in Diabetes—2025
  - 推奨: `/gdrive-sync` → `/ai-ocr 2025-ada-standards-care` → `/read-guidelines 2025-ada-standards-care`
- `2023-j-jmhc-menopause` (⚪ FOUND) — ホルモン補充療法ガイドライン2023年度版
  - 推奨: `workflow/state.md` で `APPROVED` または `SKIPPED` に更新
- `2019-j-jsh-hypertension` (⚪ FOUND) — 高血圧治療ガイドライン2019（JSH2019）
  - 推奨: `workflow/state.md` で `APPROVED` または `SKIPPED` に更新

### 高血圧 — 要アクション候補

- `2020-j-jes-cushings` (⚪ FOUND) — クッシング症候群診療ガイドライン2020
  - 推奨: `workflow/state.md` で `APPROVED` または `SKIPPED` に更新
- `2019-j-jsh-hypertension` (⚪ FOUND) — 高血圧治療ガイドライン2019（JSH2019）
  - 推奨: `workflow/state.md` で `APPROVED` または `SKIPPED` に更新

### 内分泌・代謝（副腎・下垂体・骨代謝） — 要アクション候補

- `2012-endo-soc-men1` (⚪ FOUND) — Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1): An Endocrine Society Task Force Report
  - 推奨: `workflow/state.md` で `APPROVED` または `SKIPPED` に更新
- `2016-ese-ensat-cushings` (⚪ FOUND) — Diagnosis of Endogenous Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline / ESE/ENSAT
  - 推奨: `workflow/state.md` で `APPROVED` または `SKIPPED` に更新
- `2020-j-jes-cushings` (⚪ FOUND) — クッシング症候群診療ガイドライン2020
  - 推奨: `workflow/state.md` で `APPROVED` または `SKIPPED` に更新
- `2023-j-jmhc-menopause` (⚪ FOUND) — ホルモン補充療法ガイドライン2023年度版
  - 推奨: `workflow/state.md` で `APPROVED` または `SKIPPED` に更新
- `2023-j-joa-osteoporosis` (⚪ FOUND) — 骨粗鬆症の予防と治療ガイドライン 2023年版
  - 推奨: `workflow/state.md` で `APPROVED` または `SKIPPED` に更新
- `2019-j-jsh-hypertension` (⚪ FOUND) — 高血圧治療ガイドライン2019（JSH2019）
  - 推奨: `workflow/state.md` で `APPROVED` または `SKIPPED` に更新

---

## ガイドライン一覧

| # | タイトル | 学会 | 年 | PDF | OCR | 精読 | 比較 | 臨床 | 学習 | 差分 | ステータス | エラー | 更新日 |
|---|---|---|---:|:---:|:---:|:---:|:---:|:---:|:---:|:---:|---|---|---|
| 1 | [AACE Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update](../knowledge/guidelines/2022-aace-diabetes-comprehensive-care/summary.md) | AACE | 2022 | ✅ | ✅ | ✅ | ✅ | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 2 | [AACE/ACE/AME Medical Guidelines for the Diagnosis and Management of Thyroid Nodules — 2016 Update](https://www.endocrinepractice.org/article/S1530-891X(20)44461-6/fulltext) | American Association of Clinical Endocrinologists / American College of Endocrinology / Associazione Medici Endocrinologi | 2016 | — | — | — | — | — | — | — | ⚪ FOUND |  | 2026-06-15 |
| 3 | [2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia](../knowledge/guidelines/2026-acc-aha-dyslipidemia/summary.md) | ACC/AHA | 2026 | ✅ | ✅ | ✅ | ✅ | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 4 | [2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure](../knowledge/guidelines/2022-acc-aha-heart-failure/summary.md) | ACC/AHA | 2022 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 5 | [2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults](../knowledge/guidelines/2017-acc-aha-hypertension/summary.md) | ACC/AHA | 2017 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 6 | [2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis](../knowledge/guidelines/2022-acr-glucocorticoid-osteoporosis/summary.md) | American College of Rheumatology | 2022 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 7 | [Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)](../knowledge/guidelines/2022-ada-easd-t2dm-consensus/summary.md) | American Diabetes Association / European Association for the Study of Diabetes | 2022 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 8 | [Standards of Care in Diabetes—2025](https://doi.org/10.2337/dc25-S010) | ADA（米国糖尿病学会） | 2025 | ⏭ | ⏭ | — | — | — | — | — | 🟡 APPROVED |  | 2026-06-15 |
| 9 | [Standards of Care in Diabetes—2026](../knowledge/guidelines/2026-ada-standards-care/summary.md) | ADA（米国糖尿病学会） | 2026 | ✅ | ✅ | ✅ | ✅ | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 10 | [2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis](../knowledge/guidelines/2016-ata-hyperthyroidism-thyrotoxicosis/summary.md) | American Thyroid Association | 2016 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 11 | [Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement](../knowledge/guidelines/2014-ata-hypothyroidism/summary.md) | American Thyroid Association (ATA) | 2014 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 12 | [2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer](../knowledge/guidelines/2015-ata-thyroid-nodule-dtc/summary.md) | American Thyroid Association | 2015 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 13 | [2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum](../knowledge/guidelines/2017-ata-thyroid-pregnancy/summary.md) | American Thyroid Association (ATA) | 2017 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 14 | [2021 Canadian Cardiovascular Society/Canadian Atherosclerosis Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult](../knowledge/guidelines/2021-ccs-dyslipidemia/summary.md) | CCS（カナダ心臓血管学会）/ CAS（カナダ動脈硬化学会） | 2021 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 15 | [EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)](../knowledge/guidelines/2024-easl-mafld/summary.md) | EASL / EASD / EASO | 2024 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 16 | [Acromegaly: An Endocrine Society Clinical Practice Guideline](../knowledge/guidelines/2019-endo-soc-acromegaly/summary.md) | Endocrine Society | 2019 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 17 | [Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline](../knowledge/guidelines/2016-endo-soc-adrenal-insufficiency/summary.md) | Endocrine Society | 2016 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 18 | [Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline](../knowledge/guidelines/2015-endo-soc-cushings/summary.md) | Endocrine Society | 2015 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 19 | [Growth Hormone Deficiency in Adults: An Endocrine Society Clinical Practice Guideline](../knowledge/guidelines/2019-endo-soc-ghd-adults/summary.md) | Endocrine Society | 2019 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 20 | [Hyperprolactinemia Diagnosis and Treatment: An Endocrine Society Clinical Practice Guideline](../knowledge/guidelines/2011-endo-soc-hyperprolactinemia/summary.md) | Endocrine Society | 2011 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 21 | [Hypoparathyroidism: An Endocrine Society Clinical Practice Guideline](../knowledge/guidelines/2016-endo-soc-hypoparathyroidism/summary.md) | Endocrine Society | 2016 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 22 | [Management of Diabetes and Hyperglycemia in Hospitalized Patients: An Endocrine Society Clinical Practice Guideline](../knowledge/guidelines/2022-endo-soc-inpatient-diabetes/summary.md) | Endocrine Society | 2022 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 23 | [Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline](../knowledge/guidelines/2018-endo-soc-male-hypogonadism/summary.md) | Endocrine Society | 2018 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 24 | [Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1): An Endocrine Society Task Force Report](https://academic.oup.com/jcem/article/97/9/2990/2835176) | Endocrine Society | 2012 | — | — | — | — | — | — | — | ⚪ FOUND |  | 2026-06-15 |
| 25 | [Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma (ATA MEN2 / MTC Guideline)](../knowledge/guidelines/2019-endo-soc-men2/summary.md) | American Thyroid Association（ATA）/ Endocrine Society 準拠 | 2015 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 26 | [Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline](../knowledge/guidelines/2012-endo-soc-osteoporosis-men/summary.md) | Endocrine Society | 2012 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 27 | [Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline](../knowledge/guidelines/2019-endo-soc-osteoporosis-postmenopausal/summary.md) | Endocrine Society | 2019 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 28 | [Evaluation and Treatment of Primary Hyperparathyroidism: An Endocrine Society Clinical Practice Guideline](../knowledge/guidelines/2022-endo-soc-phpt/summary.md) | Endocrine Society | 2022 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 29 | [Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline](../knowledge/guidelines/2011-endo-soc-pituitary-incidentaloma/summary.md) | Endocrine Society | 2011 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 30 | [Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline](../knowledge/guidelines/2014-endo-soc-ppgl/summary.md) | Endocrine Society | 2014 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 31 | [The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline](../knowledge/guidelines/2016-endo-soc-primary-aldosteronism/summary.md) | Endocrine Society | 2016 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 32 | [Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline](../knowledge/guidelines/2024-endo-soc-vit-d/summary.md) | Endocrine Society | 2024 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 33 | [ENETS Consensus Guidelines for Neuroendocrine Tumours (2023 Update)](../knowledge/guidelines/2023-enets-net/summary.md) | European Neuroendocrine Tumor Society（ENETS） | 2023 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 34 | [2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation](../knowledge/guidelines/2020-esc-afib/summary.md) | ESC | 2020 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 35 | [2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice](../knowledge/guidelines/2021-esc-cvd-prevention/summary.md) | ESC | 2021 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 36 | [2025 ESC/EAS Focused Update of Guidelines on Management of Dyslipidaemias](../knowledge/guidelines/2025-esc-eas-dyslipidemia/summary.md) | ESC/EAS | 2025 | ✅ | — | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 37 | [2023 ESC Guidelines on the Management of Cardiovascular Disease in Patients with Diabetes](../knowledge/guidelines/2023-esc-easd-t2dm-cvd/summary.md) | ESC/EAS | 2023 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 38 | [2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure](../knowledge/guidelines/2021-esc-heart-failure/summary.md) | ESC | 2021 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 39 | [2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure](../knowledge/guidelines/2023-esc-heart-failure/summary.md) | ESC | 2023 | ✅ | ✅ | ✅ | ✅ | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 40 | [Acromegaly management: European Pituitary Association (EPA) consensus on assessment and treatment criteria](../knowledge/guidelines/2021-ese-acromegaly/summary.md) | European Pituitary Association / European Society of Endocrinology | 2021 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 41 | [European Clinical Practice Guidelines for the Management of Obesity in Adults](https://www.endocrine-abstracts.org/ea/0090/ea0090p478) | European Society of Endocrinology / European Association for the Study of Obesity | 2023 | — | — | — | — | — | — | — | ⚪ FOUND |  | 2026-06-15 |
| 42 | [ESE and ENSAT Clinical Practice Guideline for the Diagnosis and Management of Adrenal Incidentalomas](../knowledge/guidelines/2023-ese-ensat-adrenal-incidentaloma/summary.md) | European Society of Endocrinology / ENSAT | 2023 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 43 | [Diagnosis of Endogenous Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline / ESE/ENSAT](https://academic.oup.com/jcem/article/101/5/1889/2804729) | Endocrine Society / ESE / ENSAT | 2016 | — | — | — | — | — | — | — | ⚪ FOUND |  | 2026-06-15 |
| 44 | [2023 ESH Guidelines for the Management of Arterial Hypertension](../knowledge/guidelines/2023-esh-hypertension/summary.md) | European Society of Hypertension | 2023 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 45 | [International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2023](../knowledge/guidelines/2023-eshre-pcos/summary.md) | ESHRE / ASRM / 国際多学会合同 | 2023 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 46 | [2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism](../knowledge/guidelines/2018-eta-graves/summary.md) | European Thyroid Association (ETA) | 2018 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 47 | [2019 European Thyroid Association Guidelines for the Treatment of Overt and Subclinical Hypothyroidism](../knowledge/guidelines/2019-eta-hypothyroidism/summary.md) | European Thyroid Association | 2019 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 48 | [2022 European Thyroid Association Guideline for the Management of Pediatric Graves' Disease](../knowledge/guidelines/2022-eta-pediatric-graves/summary.md) | European Thyroid Association (ETA) | 2022 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 49 | [2021 European Group on Graves' Orbitopathy (EUGOGO) Clinical Practice Guidelines for Graves' Orbitopathy](../knowledge/guidelines/2021-eugogo-graves-orbitopathy/summary.md) | European Group on Graves' Orbitopathy (EUGOGO) / European Thyroid Association (ETA) | 2021 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 50 | [Sarcopenia: Revised European Consensus on Definition and Diagnosis (EWGSOP2)](../knowledge/guidelines/2018-ewgsop2-sarcopenia/summary.md) | European Working Group on Sarcopenia in Older People（EWGSOP2） | 2018 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 51 | [ISPAD Clinical Practice Consensus Guidelines 2022](../knowledge/guidelines/2022-ispad-diabetes/summary.md) | International Society for Pediatric and Adolescent Diabetes (ISPAD) | 2022 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 52 | [動脈硬化性疾患予防ガイドライン2022年版](../knowledge/guidelines/2022-j-athero-arteriosclerosis/summary.md) | 日本動脈硬化学会 | 2022 | ✅ | ✅ | ✅ | ✅ | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 53 | [動脈硬化性疾患予防のための脂質異常症診療ガイド2023年版](../knowledge/guidelines/2023-j-athero-dyslipidemia-guide/summary.md) | 日本動脈硬化学会 | 2023 | ✅ | — | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 54 | [成人家族性高コレステロール血症診療ガイドライン フォーカスアップデート2025](../knowledge/guidelines/2025-j-athero-fh-adult/summary.md) | 日本動脈硬化学会 | 2025 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 55 | [小児家族性高コレステロール血症診療ガイドライン フォーカスアップデート2025](../knowledge/guidelines/2025-j-athero-fh-pediatric/summary.md) | 日本動脈硬化学会 | 2025 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 56 | [肥満症診療ガイドライン 2022](https://www.jasso.or.jp/) | 日本 | 2022 | — | — | — | — | — | — | — | ⚪ FOUND |  | 2026-06-15 |
| 57 | [高尿酸血症・痛風の治療ガイドライン第3版（2019年改訂版）](../knowledge/guidelines/2019-j-jatd-gout/summary.md) | 日本 | 2019 | ✅ | ✅ | — | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 58 | [2025年改訂版 心不全診療ガイドライン](../knowledge/guidelines/2025-j-jcs-heart-failure/summary.md) | JCS/JHFS | 2025 | ✅ | ✅ | ✅ | ✅ | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 59 | [糖尿病診療ガイドライン2024](../knowledge/guidelines/2024-j-jds-diabetes-guideline/summary.md) | 日本糖尿病学会 | 2024 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 60 | [糖尿病治療ガイド2024-2025](https://www.jds.or.jp/modules/publication/index.php?content_id=1) | 日本糖尿病学会 | 2024 | ⏭ | ⏭ | — | — | — | — | — | 🟡 APPROVED |  | 2026-06-15 |
| 61 | [クッシング症候群診療ガイドライン2020](https://www.j-endo.jp/modules/guideline/index.php?content_id=2) | 日本 | 2020 | — | — | — | — | — | — | — | ⚪ FOUND |  | 2026-06-15 |
| 62 | [原発性副甲状腺機能亢進症の診療ガイドライン 2021](../knowledge/guidelines/2021-j-jes-phpt/summary.md) | 日本 | 2021 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 63 | [褐色細胞腫・パラガングリオーマ診療ガイドライン2018](../knowledge/guidelines/2018-j-jes-ppgl/summary.md) | 日本 | 2018 | ✅ | ✅ | — | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 64 | [原発性アルドステロン症診断と治療のガイドライン（2021年版）](../knowledge/guidelines/2021-j-jes-primary-aldosteronism/summary.md) | 日本 | 2021 | ✅ | ✅ | — | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 65 | [ホルモン補充療法ガイドライン2023年度版](https://www.jmhc.jp/guideline/hrt.html) | 日本 | 2023 | — | — | — | — | — | — | — | ⚪ FOUND |  | 2026-06-15 |
| 66 | [骨粗鬆症の予防と治療ガイドライン 2023年版](https://www.josteo.com/) | 日本 | 2023 | — | — | — | — | — | — | — | ⚪ FOUND |  | 2026-06-15 |
| 67 | [NAFLD/NASH診療ガイドライン2023（日本消化器病学会・日本肝臓学会合同）](../knowledge/guidelines/2023-j-jsge-masld/summary.md) | 日本 | 2023 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 68 | [高血圧治療ガイドライン2019（JSH2019）](https://www.jpnsh.jp/data/jsh2019/JSH2019_hp.pdf) | 日本 | 2019 | — | — | — | — | — | — | — | ⚪ FOUND |  | 2026-06-15 |
| 69 | [AKIガイドライン2016](../knowledge/guidelines/2016-j-jsn-aki/summary.md) | 日本 | 2016 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 70 | [エビデンスに基づくCKD診療ガイドライン2023](../knowledge/guidelines/2023-j-jsn-ckd/summary.md) | 日本 | 2023 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 71 | [バセドウ病薬物療法のガイドライン2019](https://www.japanthyroid.jp/doctor/guideline/japanese.html) | 日本 | 2019 | — | — | — | — | — | — | — | ⚪ FOUND |  | 2026-06-15 |
| 72 | [橋本病（慢性甲状腺炎）診療の手引き 改訂版（2022）](https://www.japanthyroid.jp/doctor/guideline.html) | 日本 | 2022 | — | — | — | — | — | — | — | ⚪ FOUND |  | 2026-06-15 |
| 73 | [甲状腺腫瘍診療ガイドライン2018年版](../knowledge/guidelines/2024-j-jaes-thyroid-tumor/summary.md) | 日本 | 2018 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 74 | [心房細動治療（薬物）ガイドライン（2020年改訂版）](../knowledge/guidelines/2020-jcs-af/summary.md) | 日本循環器学会（JCS）/ 日本不整脈心電学会（JHRS） | 2020 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 75 | [KDIGO Clinical Practice Guideline for Acute Kidney Injury](../knowledge/guidelines/2012-kdigo-aki/summary.md) | Kidney Disease: Improving Global Outcomes (KDIGO) | 2012 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 76 | [KDIGO 2024 Clinical Practice Guideline for Anemia in Chronic Kidney Disease](../knowledge/guidelines/2024-kdigo-anemia-ckd/summary.md) | Kidney Disease: Improving Global Outcomes (KDIGO) | 2024 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 77 | [KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease](../knowledge/guidelines/2021-kdigo-bp-ckd/summary.md) | Kidney Disease: Improving Global Outcomes (KDIGO) | 2021 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 78 | [KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease](../knowledge/guidelines/2024-kdigo-ckd/summary.md) | Kidney Disease: Improving Global Outcomes (KDIGO) | 2024 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 79 | [KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)](../knowledge/guidelines/2017-kdigo-ckd-mbd/summary.md) | Kidney Disease: Improving Global Outcomes (KDIGO) | 2017 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 80 | [KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease](../knowledge/guidelines/2022-kdigo-diabetes-ckd/summary.md) | KDIGO | 2022 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 81 | [KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases](../knowledge/guidelines/2021-kdigo-glomerulonephritis/summary.md) | Kidney Disease: Improving Global Outcomes (KDIGO) | 2021 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 82 | [KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease](../knowledge/guidelines/2013-kdigo-lipids-ckd/summary.md) | Kidney Disease: Improving Global Outcomes (KDIGO) | 2013 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 83 | [The Menopause Society (NAMS) 2022 Hormone Therapy Position Statement](../knowledge/guidelines/2022-nams-menopause/summary.md) | North American Menopause Society（NAMS / The Menopause Society） | 2022 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 84 | [NCCN Clinical Practice Guidelines in Oncology — Thyroid Carcinoma, Version 1.2025](../knowledge/guidelines/2025-nccn-thyroid-carcinoma/summary.md) | National Comprehensive Cancer Network (NCCN) | 2025 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 85 | [Chronic kidney disease: assessment and management (NICE NG203, updated 2023)](../knowledge/guidelines/2021-nice-ckd/summary.md) | NICE | 2021 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 86 | [NICE NG238 Cardiovascular disease: risk assessment and reduction, including lipid modification](../knowledge/guidelines/2023-nice-cvd-lipid/summary.md) | NICE | 2023 | ✅ | ✅ | ✅ | ✅ | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 87 | [Chronic heart failure in adults: diagnosis and management (NICE NG106, updated 2023)](../knowledge/guidelines/2018-nice-heart-failure/summary.md) | NICE | 2018 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 88 | [Hypertension in adults: diagnosis and management (NICE NG136, updated 2023)](../knowledge/guidelines/2019-nice-hypertension/summary.md) | NICE | 2019 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 89 | [Obesity: identification, assessment and management (NICE CG189, updated 2023)](../knowledge/guidelines/2014-nice-obesity/summary.md) | NICE | 2014 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 90 | [Osteoporosis: assessing the risk of fragility fracture (NICE CG146, updated 2017)](../knowledge/guidelines/2012-nice-osteoporosis-fragility/summary.md) | NICE | 2012 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 91 | [Thyroid disease: assessment and management (NICE NG145)](../knowledge/guidelines/2019-nice-thyroid-disease/summary.md) | NICE | 2019 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 92 | [Type 1 diabetes in adults: diagnosis and management (NICE NG17, updated 2022)](../knowledge/guidelines/2022-nice-type1-diabetes/summary.md) | NICE | 2022 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 93 | [Type 2 diabetes in adults: management (NICE NG28)](../knowledge/guidelines/2022-nice-type2-diabetes/summary.md) | NICE | 2022 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 94 | [Statin Use for the Primary Prevention of Cardiovascular Events in Adults: US Preventive Services Task Force Recommendation Statement](../knowledge/guidelines/2022-uspstf-statin-prevention/summary.md) | USPSTF（米国予防医療サービス作業部会） | 2022 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |
| 95 | [WHO Guideline for the Pharmacological Treatment of Hypertension in Adults](../knowledge/guidelines/2021-who-hypertension/summary.md) | World Health Organization | 2021 | ✅ | ✅ | ✅ | — | ✅ | ✅ | — | 🔵 LEARNED |  | 2026-06-15 |

---

## エラー詳細

エラーなし

---

## 次のアクション候補

以下のガイドラインが **APPROVED** 状態で精読待ちです:

- `2025-ada-standards-care` — Standards of Care in Diabetes—2025
  - 推奨: `/gdrive-sync` → `/ai-ocr 2025-ada-standards-care` → `/read-guidelines 2025-ada-standards-care`
- `2024-j-jds-diabetes-treatment-guide` — 糖尿病治療ガイド2024-2025
  - 推奨: `/gdrive-sync` → `/ai-ocr 2024-j-jds-diabetes-treatment-guide` → `/read-guidelines 2024-j-jds-diabetes-treatment-guide`

---

*このファイルは `scripts/build_status_md.py` で自動生成されます。*  
*ダッシュボード: [dashboard/index.html](../dashboard/index.html)*